Canadian Cannabis: Is Canopy Growth (TSX:WEED) Stock Still a Buy Right Now?

At least three Canadian cannabis stocks have good cash runways, but how does Canopy Growth Corp (TSX:WEED)(NYSE:CGC) compare?

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

It used to be profitability that signified a Canadian cannabis stock’s biggest buy signal. Right now, though, it’s cash runway. Profitability is still crucial, but cash is key in the race for survival. And not all Canadian cannabis stocks are going to survive. “Survive now, thrive later” is the name of the game. So, which companies are likeliest to get through to the final round? Let’s take a look at the biggest names.

The three “safest” Canadian cannabis companies

There’s no such thing as a safe Canadian cannabis stock. Not yet, anyway. However, three big names stand out because of their cash runways. Which one is a better buy?

Canopy Growth (TSX:WEED)(NYSE:CGC) is often held up as being the one stock to buy for eventual cannabis market dominance. Gone are the days of high momentum. Long positions are now the surest way to play the unsettled cannabis space. Stocks like Canopy have buckets of cash on hand, making them the safest bets — not that any cannabis stock can be considered safe in the current economic climate.

Cronos Group is still sitting on a pot of gold after its Altria Group cash injection. $2 billion can go a long way — about 140 months, to be precise. Capacity is king for this lighter-weight Canadian cannabis player due for an earnings report. The company is highly maneuverable, with smaller assets and a focus on building a name. This model allows the company to outsource supply and drill down on getting that brand out there.

Matching cash with performance

Aphria has enough in the kitty to live off for almost two years. Compare this with a struggling Canadian cannabis sector that often has a quarter of that cash. This popular name has a run of decent quarters under its belt. Look at that +450% revenue boost back in January. Supply is still an issue, but this shouldn’t be a long-term thing. The company’s outlook is solid for 2020, and how many companies can say that right now?

Canopy Growth is a little behind Aphria with an 18-month cash runway. This is still impressive by the sector’s standards. However, the lower-risk investor may want to plump for one of Canopy’s aforementioned competitors. One thing that Canopy has going for it, though, is diversification. The company was strongly focused on acquisitions for a while. This has left it with a broad income base.

The company is also big on branding, pulling in big-name celebrity endorsements. Its management is also infused with corporate know-how from Constellation Brands. The company has been stripped back, making for a lighter operation. It’s still one of the more solid Canadian cannabis stocks, given that executive expertise and $2.3 billion in cash.

The bottom line

Investing in Canadian cannabis isn’t done yet. The industry sits at an intriguing intersection of sin stocks and healthcare, and could prove recession-proof. Positive momentum hasn’t entirely left the sector, either. The best names are the ones slashing capex and focusing on profitability. Upside could therefore reward investors in these three stocks most likely to survive the next 18 months.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Victoria Hetherington has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Constellation Brands.

More on Cannabis Stocks

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Should You Stay Away From HEXO Stock?

HEXO (TSX:HEXO)(NASDAQ:HEXO) stock is on a downward spiral, and there is little hope it is going to recover soon.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why Did Aurora Cannabis (TSX:ACB) Stock Plunge 75% in 2022?

A prominent cannabis stock has plunged by 75% in 2022, as the company’s losses continue to mount in the face…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Fire & Flower: A Small Pot Stock Poised for Strong Growth

Fire & Flower is a cannabis retailer well-positioned for growth thanks to its digital and delivery initiatives.

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Aurora Cannabis (TSX:ACB) Stock Is Sinking This Week

Starting another round of capital raising has hurt investor sentiments, and the Canadian cannabis giant’s performance on the stock market…

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Canopy Growth (TSX:WEED) Stock Plunged 19% Last Week

Canopy Growth Corp. (TSX:WEED)(NASDAQ:CGC) stock has plunged after the release of its final fiscal 2022 results.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

Why Aurora Cannabis (TSX:ACB) Stock Tanked 45% Last Week

There's no respite for Aurora Cannabis investors!

Read more »

Money growing in soil , Business success concept.
Cannabis Stocks

TFSA Investors: This Undervalued Gem Could Turn $6,000 Into $25,000

Here's why TFSA investors can hold undervalued growth stocks such as Verano in their portfolios right now.

Read more »

TSX Today
Cannabis Stocks

TSX Today: What to Watch for in Stocks on Monday, May 30

TSX investors should keep a close eye on the latest manufacturing data from China today.

Read more »